| pubmed-article:15623610 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0162488 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0884358 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0443211 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:15623610 | lifeskim:mentions | umls-concept:C1516463 | lld:lifeskim |
| pubmed-article:15623610 | pubmed:issue | 24 | lld:pubmed |
| pubmed-article:15623610 | pubmed:dateCreated | 2004-12-29 | lld:pubmed |
| pubmed-article:15623610 | pubmed:abstractText | Use of surrogate end point biomarkers in phase II trials may help select agents that appear to have activity and might be evaluated in future phase III definitive trials of breast cancer prevention. We performed a pilot clinical trial to establish the logistics for a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with novel imaging techniques and candidate surrogate end point biomarkers for activity. We chose tamoxifen to establish proof of principal with a known effective agent. | lld:pubmed |
| pubmed-article:15623610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623610 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15623610 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623610 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15623610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623610 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15623610 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15623610 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:SinghBaljitB | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:IsaacsClaudin... | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:HayesDaniel... | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:KleerCelina... | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:HaddadBassem... | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:StearnsVeredV | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:GallagherAnnA | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:FreedmanMatth... | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:BrownMarthaM | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:TrockBruceB | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:WarrenRobertR | lld:pubmed |
| pubmed-article:15623610 | pubmed:author | pubmed-author:CullenJennife... | lld:pubmed |
| pubmed-article:15623610 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15623610 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15623610 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15623610 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15623610 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15623610 | pubmed:pagination | 8332-40 | lld:pubmed |
| pubmed-article:15623610 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:meshHeading | pubmed-meshheading:15623610... | lld:pubmed |
| pubmed-article:15623610 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15623610 | pubmed:articleTitle | A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. | lld:pubmed |
| pubmed-article:15623610 | pubmed:affiliation | Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. vstearn1@jhmi.edu | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:15623610 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
